Efficacy of Adoptively Transferred Allogeneic Cik Cells on Colorectal Cancer: Augmentative Antitumoral Effects of Gvhd Publisher Pubmed



Muhammadnejad S¹ ; Monzavi SM^{1, 2} ; Torabirahvar M³ ; Sotoudeh M⁴ ; Muhammadnejad A⁵ ; Tavakolishiraji S⁶ ; Ranjbar A^{1, 7} ; Aghayan SS^{1, 7} ; Khorsand AA¹ ; Moradzadeh K^{1, 7} ; Janzamin E⁸ ; Ahmadbeigi N^{1, 7}
Source: International Immunopharmacology Published:2023

Abstract

Objective: A preclinical study was designed to evaluate the effects of adoptively transferred cytokine-induced killer (CIK) cells on colorectal adenocarcinoma. Methods: Forty NOG mice bearing HT-29 xenograft tumors were developed and equally divided into 2 groups of treatment and control. The mice in the treatment group received cumulatively 40–60 × 106 CIK cells in four divided doses. Results: Median tumor doubling times for HT-29 xenograft tumors in the treatment and control groups were found to be 8.98 and 4.32 days; respectively. The treatment resulted in tumor growth delay (TGD) of 52.5 %. CIK cell-induced log cell kill (LCK) was found to be 0.67, which implies reduction of 78.6 % of neoplastic colorectal cells. Median length of survival in the treated mice was significantly longer than controls (57 (41–63) vs 41 (31–57) days, P < 0.001). Mice in the treatment group experienced graft-versus-host disease (GvHD) from median of day 13th after the cell therapy. LCK and TGD significantly increased after emergence of GvHD. After necropsy, tumors of the treatment group contained high levels of human-originated CD3+, CD4+ and CD8+ cells and showed significantly lower mitotic counts (P < 0.001) and residual tumor scores (P = 0.005) than the controls (entirely negative for the mentioned CD markers). Ninety percent of the treated mice were found to be responding. Conclusions: Adoptive transfer of allogeneic CIK cells may be an efficient antitumoral therapy for colorectal cancer. Allogeneic CIK cell-mediated GvHD may contribute to amplification of graft-versus-tumor effects of the cellular therapy. © 2022 Elsevier B.V.